Status:
COMPLETED
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
Lead Sponsor:
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants. This study will involve a...
Eligibility Criteria
Inclusion
- Body mass index (BMI) ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 at Screening; body weight
- ≥ 55.0 kg and ≤ 100.0 kg at Screening.
- Negative serology results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) and human immunodeficiency virus antibody and antigen (HIV Ab/Ag).
- Non-smoker (with no use of other tobacco or nicotine containing products, in any form), as documented by history (no nicotine within 6 months prior to Screening) and a negative cotinine test at Screening and admission
Exclusion
- History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor
- Any history of serious allergic/hypersensitivity reactions
- History or presence of alcohol or drug abuse (self-reported) within 2 years prior to Screening.
- Administration of any prescription or non-prescription drugs (including antacids; however, acetaminophen at a dose ≤ 1 g/day is permitted), herbal remedies or vitamin supplements from 28 days, or five half-lives, whichever is longer, prior to Admission.
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06901336
Start Date
March 20 2025
End Date
May 6 2025
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmaron Clinical Pharmacology Center Inc
Baltimore, Maryland, United States, 42374